LEK-8827
| Clinical data | |
|---|---|
| Other names | 6-Methyl-LEK-8842; 6-Methyl-N-methyl-N-(2-propynyl)lysergamide |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| PubChem SID | |
| Chemical and physical data | |
| Formula | C21H24N3O+ |
| Molar mass | 334.443 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
LEK-8827, also known as 6-methyl-LEK-8842 or as 6-methyl-N-methyl-N-(2-propynyl)lysergamide, is a chemical compound of the lysergamide family.[1] It is the 6-methyl derivative of LEK-8842 and is a quaternary ammonium compound.[1] The drug shows almost complete elimination of affinity for serotonin 5-HT2 and α-adrenergic receptors compared to LEK-8842, with no affinity for serotonin 5-HT2 receptors and slight but negligible affinity for α-adrenergic receptors.[1] Its loss of activity was said to probably be due to the increased polarity of the molecule.[1] LEK-8827 was first described in the scientific literature by 1992.[1] It was developed by the Slovenian pharmaceutical company LEK Pharmaceuticals.[1]
See also
- Substituted lysergamide
- LEK-8842
- Nor-LSD (6-nor-LSD)
References
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.